Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Dynamic cross-regulation of antigen-specific effector and regulatory T cell subpopulations and microglia in brain autoimmunity

  • Martínez Pasamar, Sara
  • Abad Adan, Elena
  • Moreno, Beatriz
  • Vélez de Mendizábal, Nieves
  • Martínez Forero, Ivan
  • García Ojalvo, Jordi
  • Villoslada, Pablo
Background: Multiple Sclerosis (MS) is considered a T-cell-mediated autoimmune disease with a prototypical oscillatory behavior, as evidenced by the presence of clinical relapses. Understanding the dynamics of immune cells governing the course of MS, therefore, has many implications for immunotherapy. Here, we used flow cytometry to analyze the time-dependent behavior of antigen-specific effector (Teff) and regulatory (Treg) T cells and microglia in mice model of MS, Experimental Autoimmune Encephalomyelitis (EAE), and compared the observations with a mathematical cross-regulation model of T-cell dynamics in autoimmune disease. Results: We found that Teff and Treg cells specific to myelin olygodendrocyte glycoprotein (MOG) developed coupled oscillatory dynamics with a 4- to 5-day period and decreasing amplitude that was always higher for the Teff populations, in agreement with the mathematical model. Microglia activation followed the oscillations of MOG-specific Teff cells in the secondary lymphoid organs, but they were activated before MOG-specific T-cell peaks in the CNS. Finally, we assessed the role of B-cell depletion induced by anti-CD20 therapy in the dynamics of T cells in an EAE model with more severe disease after therapy. We observed that B-cell depletion decreases Teff expansion, although its oscillatory behavior persists. However, the effect of B cell depletion was more significant in the Treg population within the CNS, which matched with activation of microglia and worsening of the disease. Mathematical modeling of T-cell cross-regulation after anti-CD20 therapy suggests that B-cell depletion may influence the dynamics of T cells by fine-tuning their activation. Conclusions: The oscillatory dynamics of T-cells have an intrinsic origin in the physiological regulation of the adaptive immune response, which influences both disease phenotype and response to immunotherapy., This work was supported in part by the Spanish network of excellence in MS of the Instituto de Salud Carlos III, Spain to PV and JGO (RD07/0060), by grant FIS-PI12/01823, the European Commission 7FP (CombiMS, contract grant: 305397), and by an unrestricted grant from Roche to PV; a grant of the Ministerio de Ciencia e Innovación (Spain, project FIS2009-13360) and by the ICREA Academia program to JGO
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Dynamics and heterogeneity of brain damage in multiple sclerosis

  • Kotelnikova, Ekaterina
  • Kiani, Narsis A.
  • Abad Adan, Elena
  • Martínez Lapiscina, Elena H.
  • Andorrà, Magí
  • Zubizarreta, Irati
  • Pulido Valdeolivas, Irene
  • Pertsovskaya, Inna
  • Alexopoulos, Leonidas G.
  • Olsson, Tomas
  • Martin, Roland
  • Paul, Friedemann
  • Tegnér, Jesper
  • García Ojalvo, Jordi
  • Villoslada, Pablo
Multiple Sclerosis (MS) is an autoimmune disease driving inflammatory and degenerative processes that damage the central nervous system (CNS). However, it is not well understood how these events interact and evolve to evoke such a highly dynamic and heterogeneous disease. We established a hypothesis whereby the variability in the course of MS is driven by the very same pathogenic mechanisms responsible for the disease, the autoimmune attack on the CNS that leads to chronic inflammation, neuroaxonal degeneration and remyelination. We propose that each of these processes acts more or less severely and at different times in each of the clinical subgroups. To test this hypothesis, we developed a mathematical model that was constrained by experimental data (the expanded disability status scale [EDSS] time series) obtained from a retrospective longitudinal cohort of 66 MS patients with a long-term follow-up (up to 20 years). Moreover, we validated this model in a second prospective cohort of 120 MS patients with a three-year follow-up, for which EDSS data and brain volume time series were available. The clinical heterogeneity in the datasets was reduced by grouping the EDSS time series using an unsupervised clustering analysis. We found that by adjusting certain parameters, albeit within their biological range, the mathematical model reproduced the different disease courses, supporting the dynamic CNS damage hypothesis to explain MS heterogeneity. Our analysis suggests that the irreversible axon degeneration produced in the early stages of progressive MS is mainly due to the higher rate of myelinated axon degeneration, coupled to the lower capacity for remyelination. However, and in agreement with recent pathological studies, degeneration of chronically demyelinated axons is not a key feature that distinguishes this phenotype. Moreover, the model reveals that lower rates of axon degeneration and more rapid remyelination make relapsing MS more resilient than the progressive subtype. Therefore, our results support the hypothesis of a common pathogenesis for the different MS subtypes, even in the presence of genetic and environmental heterogeneity. Hence, MS can be considered as a single disease in which specific dynamics can provoke a variety of clinical outcomes in different patient groups. These results have important implications for the design of therapeutic interventions for MS at different stages of the disease., The European Union Seventh Framework Program (HEALTH-F4-2012-305397): “CombiMS”, grant agreement No 30539; the Horizon 2020 program ERACOSYSMED: Sys4MS grant, and the Spanish Ministry of Economy and Competitiveness and FEDER (project FIS2015-66503-C3-1-P), and the Swedish Research Council (3R).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Prediction of combination therapies based on topological modeling of the immune signaling network in multiple sclerosis

  • Bernardo-Faura, Martí
  • Rinas, Melanie
  • Wirbel, Jakob
  • Pertsovskaya, Inna
  • Pliaka, Vicky
  • Messinis, Dimitris E.
  • Vila, Gemma
  • Sakellaropoulos, Theodore
  • Faigle, Wolfgang
  • Stridh, Pernilla
  • Behrens, Janina R.
  • Olsson, Tomas
  • Martin, Roland
  • Paul, Friedemann
  • Alexopoulos, Leonidas G.
  • Villoslada, Pablo
  • Sáez-Rodríguez, Julio
This work was supported by the European Union 7FP-Programme (CombiMS, grant No 305397) and the European Sys4MS project (Horizon2020: Eracosysmed: ID-43). RM and the Section for Neuroimmunology and MS Research, University Zurich (UZH), have been supported by a European Research Council Advanced Grant (ERC 340733-HLA-DR15 in MS), by a Clinical Research Priority Project - disease heterogeneity of MS (CRPPMS; UZH), by the Swiss National Science Foundation and the Swiss MS Society. Open Access funding enabled and organized by Projekt DEAL., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Dynamics and heterogeneity of brain damage in multiple sclerosis

  • Kotelnikova, Ekaterina
  • Kiani, Narsis A.
  • Abad Adan, Elena
  • Martínez Lapiscina, Elena H.
  • Andorrà, Magí
  • Zubizarreta, Irati
  • Pulido Valdeolivas, Irene
  • Pertsovskaya, Inna
  • Alexopoulos, Leonidas G.
  • Olsson, Tomas
  • Martin, Roland
  • Paul, Friedemann
  • Tegnér, Jesper
  • García Ojalvo, Jordi
  • Villoslada, Pablo
Multiple Sclerosis (MS) is an autoimmune disease driving inflammatory and degenerative processes that damage the central nervous system (CNS). However, it is not well understood how these events interact and evolve to evoke such a highly dynamic and heterogeneous disease. We established a hypothesis whereby the variability in the course of MS is driven by the very same pathogenic mechanisms responsible for the disease, the autoimmune attack on the CNS that leads to chronic inflammation, neuroaxonal degeneration and remyelination. We propose that each of these processes acts more or less severely and at different times in each of the clinical subgroups. To test this hypothesis, we developed a mathematical model that was constrained by experimental data (the expanded disability status scale [EDSS] time series) obtained from a retrospective longitudinal cohort of 66 MS patients with a long-term follow-up (up to 20 years). Moreover, we validated this model in a second prospective cohort of 120 MS patients with a three-year follow-up, for which EDSS data and brain volume time series were available. The clinical heterogeneity in the datasets was reduced by grouping the EDSS time series using an unsupervised clustering analysis. We found that by adjusting certain parameters, albeit within their biological range, the mathematical model reproduced the different disease courses, supporting the dynamic CNS damage hypothesis to explain MS heterogeneity. Our analysis suggests that the irreversible axon degeneration produced in the early stages of progressive MS is mainly due to the higher rate of myelinated axon degeneration, coupled to the lower capacity for remyelination. However, and in agreement with recent pathological studies, degeneration of chronically demyelinated axons is not a key feature that distinguishes this phenotype. Moreover, the model reveals that lower rates of axon degeneration and more rapid remyelination make relapsing MS more resilient than the progressive subtype. Therefore, our results support the hypothesis of a common pathogenesis for the different MS subtypes, even in the presence of genetic and environmental heterogeneity. Hence, MS can be considered as a single disease in which specific dynamics can provoke a variety of clinical outcomes in different patient groups. These results have important implications for the design of therapeutic interventions for MS at different stages of the disease., The European Union Seventh Framework Program (HEALTH-F4-2012-305397): “CombiMS”, grant agreement No 30539; the Horizon 2020 program ERACOSYSMED: Sys4MS grant, and the Spanish Ministry of Economy and Competitiveness and FEDER (project FIS2015-66503-C3-1-P), and the Swedish Research Council (3R).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Dynamic cross-regulation of antigen-specific effector and regulatory T cell subpopulations and microglia in brain autoimmunity

  • Martínez Pasamar, Sara
  • Abad Adan, Elena
  • Moreno, Beatriz
  • Vélez de Mendizábal, Nieves
  • Martínez Forero, Ivan
  • García Ojalvo, Jordi
  • Villoslada, Pablo
Background: Multiple Sclerosis (MS) is considered a T-cell-mediated autoimmune disease with a prototypical oscillatory behavior, as evidenced by the presence of clinical relapses. Understanding the dynamics of immune cells governing the course of MS, therefore, has many implications for immunotherapy. Here, we used flow cytometry to analyze the time-dependent behavior of antigen-specific effector (Teff) and regulatory (Treg) T cells and microglia in mice model of MS, Experimental Autoimmune Encephalomyelitis (EAE), and compared the observations with a mathematical cross-regulation model of T-cell dynamics in autoimmune disease. Results: We found that Teff and Treg cells specific to myelin olygodendrocyte glycoprotein (MOG) developed coupled oscillatory dynamics with a 4- to 5-day period and decreasing amplitude that was always higher for the Teff populations, in agreement with the mathematical model. Microglia activation followed the oscillations of MOG-specific Teff cells in the secondary lymphoid organs, but they were activated before MOG-specific T-cell peaks in the CNS. Finally, we assessed the role of B-cell depletion induced by anti-CD20 therapy in the dynamics of T cells in an EAE model with more severe disease after therapy. We observed that B-cell depletion decreases Teff expansion, although its oscillatory behavior persists. However, the effect of B cell depletion was more significant in the Treg population within the CNS, which matched with activation of microglia and worsening of the disease. Mathematical modeling of T-cell cross-regulation after anti-CD20 therapy suggests that B-cell depletion may influence the dynamics of T cells by fine-tuning their activation. Conclusions: The oscillatory dynamics of T-cells have an intrinsic origin in the physiological regulation of the adaptive immune response, which influences both disease phenotype and response to immunotherapy., This work was supported in part by the Spanish network of excellence in MS of the Instituto de Salud Carlos III, Spain to PV and JGO (RD07/0060), by grant FIS-PI12/01823, the European Commission 7FP (CombiMS, contract grant: 305397), and by an unrestricted grant from Roche to PV; a grant of the Ministerio de Ciencia e Innovación (Spain, project FIS2009-13360) and by the ICREA Academia program to JGO
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Prediction of combination therapies based on topological modeling of the immune signaling network in multiple sclerosis

  • Bernardo-Faura, Martí|||0000-0002-8023-3263
  • Rinas, Melanie
  • Wirbel, Jakob|||0000-0002-4073-3562
  • Pertsovskaya, Inna
  • Pliaka, Vicky
  • Messinis, Dimitris E.
  • Vila, Gemma
  • Sakellaropoulos, Theodore
  • Faigle, Wolfgang
  • Stridh, Pernilla|||0000-0003-4855-0039
  • Behrens, Janina R.
  • Olsson, Tomas
  • Martin, Roland|||0000-0002-0982-1329
  • Paul, Friedemann|||0000-0002-6378-0070
  • Alexopoulos, Leonidas G.
  • Villoslada, P.|||0000-0002-8735-6119
  • Saez-Rodriguez, Julio|||0000-0002-8552-8976
Multiple sclerosis (MS) is a major health problem, leading to a significant disability and patient suffering. Although chronic activation of the immune system is a hallmark of the disease, its pathogenesis is poorly understood, while current treatments only ameliorate the disease and may produce severe side effects. Here, we applied a network-based modeling approach based on phosphoproteomic data to uncover the differential activation in signaling wiring between healthy donors, untreated patients, and those under different treatments. Based in the patient-specific networks, we aimed to create a new approach to identify drug combinations that revert signaling to a healthy-like state. We performed ex vivo multiplexed phosphoproteomic assays upon perturbations with multiple drugs and ligands in primary immune cells from 169 subjects (MS patients, n=129 and matched healthy controls, n=40). Patients were either untreated or treated with fingolimod, natalizumab, interferon-β, glatiramer acetate, or the experimental therapy epigallocatechin gallate (EGCG). We generated for each donor a dynamic logic model by fitting a bespoke literature-derived network of MS-related pathways to the perturbation data. Last, we developed an approach based on network topology to identify deregulated interactions whose activity could be reverted to a "healthy-like" status by combination therapy. The experimental autoimmune encephalomyelitis (EAE) mouse model of MS was used to validate the prediction of combination therapies. Analysis of the models uncovered features of healthy-, disease-, and drug-specific signaling networks. We predicted several combinations with approved MS drugs that could revert signaling to a healthy-like state. Specifically, TGF-β activated kinase 1 (TAK1) kinase, involved in Transforming growth factor β-1 proprotein (TGF-β), Toll-like receptor, B cell receptor, and response to inflammation pathways, was found to be highly deregulated and co-druggable with all MS drugs studied. One of these predicted combinations, fingolimod with a TAK1 inhibitor, was validated in an animal model of MS. Our approach based on donor-specific signaling networks enables prediction of targets for combination therapy for MS and other complex diseases.